The DelveInsight Traveler’s Diarrhea market report gives a thorough understanding of the Traveler’s Diarrhea by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Traveler’s Diarrhea (TD) is an intestinal infection, a digestive tract disorder that is caused by a variety of pathogens but most commonly by bacteria found in food and water, often related to poor hygiene practices. Being the most predictable disease, around 30% to 70% of the travelers are found to suffer from it.

Traveler’s Diarrhea Epidemiology

DelveInsight’s assessment based on the recent studies and data from registries shows that the European 5 countries and US accounts for the 43.4% and 40.77% of the total Incident cases out of all the TD cases in 7 major markets in 2017.

The Traveler’s Diarrhea epidemiology division provide insights about historical and current Traveler’s Diarrheapatient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

As per DelveInsight’s estimates, in 2017 only the European 5 countries and the US accounted for about 43.4% and 40.77% of the total Traveler’s Diarrhea Incident cases out of all the TD cases in 7 major markets.

Traveler’s Diarrhea Epidemiology Segmentation

Total Traveler’s Diarrhea Incident Cases

Total Diagnosed Traveler’s Diarrhea Incident Cases

Severity-Specific Diagnosed Traveler’s Diarrhea Incident Cases

Traveler’s Diarrhea treatment Market

The Traveler’s Diarrhea Treatment Market comprises of anti-motility drugs or Antidiarrheal drugs (also known as symptomatic therapy) including bismuth subsalicylate and Synthetic opiates such as loperamide and diphenoxylate, with ciprofloxacin, ofloxacin, norfloxacin and levofloxacin and Dukarol (Vaccine) dominating the market as first line of therapy.

According to DelveInsight, Traveler’s Diarrhea market in 7MM is expected to increase in the study period 2017-2030 from USD 1,717 Million in 2017. The United States accounts for the largest Traveler’s Diarrhea market size, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan owing to the largest number of incident population.

The Traveler’s Diarrhea market report provides current treatment practices, emerging drugs, Traveler’s Diarrhea market share of the individual therapies, current and forecasted Traveler’s Diarrhea market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Traveler’s Diarrhea treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Key pharma players such as Scandinavian Biopharma, Procter and Gamble, and others have the potential to create a significant positive shift in the Traveler’s Diarrhea Market Size.

The late stage product BismuthSubsalicylate has emerged as a promising option to enter the market in 2021 for Traveler’s Diarrhea. Another mid stage product Etvax is a vaccine against diarrheal disease caused by ETEC expected to enter the market by 2023.

Scope of the report

Descriptive overview of Traveler’s Diarrhea, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies

Comprehensive insight has been provided into the Traveler’s Diarrhea epidemiology and treatment in the 7MM

In-depth account of both the current and emerging therapies for Traveler’s Diarrhea along with the assessment of new therapies

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.